Loading organizations...
§ Venture Capital · Durham, NC, USA
Bio-pharmaceuticals company developing and delivering treatments, accelerating innovation for infectious diseases in China.
Brii Biosciences is a biopharmaceutical company developing and commercializing novel treatments for infectious diseases, operating with dual headquarters in Shanghai, China, and Durham, North Carolina. The firm focuses on accelerating medical innovation across the Greater China market by utilizing strategic partnerships and securing exclusive regional licensing agreements for promising clinical assets. To support its extensive clinical research and regional commercialization efforts, the enterprise successfully launched with $260 million in initial venture capital funding. Its financial backing comes from a syndicate of prominent institutional investors, specifically including ARCH Venture Partners, Sequoia Capital, and Boyu Capital. Additionally, the organization actively collaborates with established industry entities such as Vir Biotechnology and Alibaba's AliHealth to advance its drug development pipelines and integrate digital healthcare tools. Brii Biosciences was officially founded in 2018 by its chief executive officer Zhi Hong.
Brii Biosciences has raised $415.0M across 2 funding rounds.
Key people at Brii Biosciences.
Brii Biosciences was founded in 2018 by Zhi Hong (Co-Founder and Chief Executive Officer).
Brii Biosciences has raised $415.0M in total across 2 funding rounds.
Brii Biosciences was founded in 2018 by Zhi Hong (Co-Founder and Chief Executive Officer).
Brii Biosciences has raised $415.0M in total across 2 funding rounds.
Brii Biosciences's investors include Invesco, GIC, Lake Bleu Capital, Leon Chen, Robert Nelsen, Blue Pool Capital, Sean Tong, Neil Shen, David Yu.
Key people at Brii Biosciences.
Brii Biosciences has raised $415.0M across 2 funding rounds. Most recently, it raised $155.0M Series C in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 23, 2021 | $155M Series C | Invesco | GIC, Lake Bleu Capital | Announced |
| May 24, 2018 | $260M Venture Round | — | Leon Chen, Robert Nelsen, Blue Pool Capital, Sean Tong, Neil Shen, David YU | Announced |